An EZH2 inhibitor (PF-06821497) developed by Pfizer has entered phase 1 testing in patients with small cell lung cancer, castration-resistant prostate cancer, and follicular lymphoma (NCT03460977). Here, EZH2 is linked to follicular lymphoma.